至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity

Front Immunol. 2021-07; 
Matteo Rossi, Susanna Carboni, Wilma Di Berardino-Besson, Erika Riva, Marie-Laure Santiago-Raber, Elodie Belnoue, Madiha Derouazi
Products/Services Used Details Operation
Bacterial Expression … Vaccine constructs were designed in-house and produced in E. coli by Genscript … stimulant as a negative control in the presence of Golgi stop (BD biosciences) and a fluorochrome coupled anti-CD107α for 6 h. After washing, cells were stained for cell surface antigens … Get A Quote

摘要

Combining different immunotherapy approaches is currently building the future of immunotherapy, with the view to maximize anti-tumoral efficacy for larger patient population. The KISIMA™ platform allows the development of protein-based cancer vaccines able to induce tumor-specific T cell response resulting in anti-tumoral efficacy in various mouse models. Intra-tumoral administration of stimulator of interferon gene agonists (STINGa) was shown to induce a potent inflammatory response leading to the development of tumor-specific immunity. Here, we explored the efficacy and mechanisms of action of subcutaneous STINGa treatment combined with therapeutic vaccination in various mouse tumor models. This combinatory... More

关键词

CD8 T cells functionality, STING agonist, Th1 CD4 T cells, combination immunotherapy, protein cancer vaccine, tumor microenvironment